News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Active Biotech AB (BTPC)'s Partner Ipsen (IPN.PA) Initiates a Proof-of-Concept Study With Tasquinimod in Additional Cancer Indications


10/19/2012 8:48:43 AM

Lund, Sweden, October 19, 2012 - Active Biotech (NASDAQ OMX NORDIC: ACTI) today announces that its partner Ipsen (Euronext: IPN; ADR: IPSEY, read press release here) will initiate a new phase II, proof-of-concept clinical trial with tasquinimod in a so-called umbrella study evaluating the compound in four different tumor types.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES